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Normal human melanocytes respond to endothelin-1
with induced proliferation and differentiation.
Whereas in cultured melanoma cells the predomin-
ant endothelin receptor, ET(B)-R, is consistently
downregulated, ET(B)-R upregulation was recently
reported for melanoma tumors. Contrary to the pro-
survival activity described for endothelin in vascular
cells, a proapoptotic activity of endothelin-1 has
been reported for melanoma cells, in previous stud-
ies. We therefore investigated the role of endothelin
for melanoma cells with respect to apoptosis and
proliferation. Treatment with 10 nM endothelin-1
was a strong mitogenic signal for normal human
melanocytes, which responded with a 4±6-fold
increase of thymidine incorporation, whereas the
response was only 1.2-fold for SK-Mel-19, the mela-
noma cell line characterized by the highest ET(B)-R
expression, and it was even less in other cell lines.
Determination of the apoptotic rates revealed that
endothelin-1 signi®cantly reduced basic apoptotic
rates to 75% both in SK-Mel-19 and in normal mela-
nocytes. After cell synchronization, an antiapoptotic
effect of endothelin-1 was seen in ®ve of seven cell
lines investigated. In the cell line Bro, which showed
no response and which lacks ET(B)-R expression,
responsibility could be restored by overexpression of
ET(B)-R after stable transfection, indicating that the
effectors of the endothelin-1 signal cascade were
active in these cells, and that the antiapoptotic effect
of endothelin-1 is mediated in a receptor-speci®c
way. This antiapoptotic activity of endothelin for
melanoma cells combined with upregulation of
endothelin receptors in the tumor may be a crucial




ndothelins (ET-1, ET-2, ET-3) are paracrine signal
peptides of 21 amino acid residues that bind to two
highly homologous, G-protein-coupled, heptahelical
receptors, ET(A)-R and ET(B)-R (Elshourbagy et al,
1993). As a predominant activity in the vascular
system, where ETs were ®rst studied, they cause vasoconstric-
tion of smooth muscle cells, but in various nonvascular cells
effects on proliferation as well as on differentiation have also
been reported (Simonson and Dunn, 1990). Normal human
melanocytes were shown to bind ET-1 and respond with
increased proliferation and pigmentation (Yada et al, 1991).
According to a recent model, ET-1 secretion of epidermal
keratinocytes is upregulated by ultraviolet (UV) irradiation
resulting in enhanced melanocyte proliferation and pigment
production leading to skin tanning (Imokawa et al, 1992; Yohn
et al, 1993). Mutation of the ET(B)-R gene is associated with
megacolon and pigmentary disorders in human patients indicat-
ing its important role also for neural crest cell migration in
embryogenesis (Puffenberger et al, 1994).
The study of aberrant gene expression can provide considerable
insight into the characteristics of malignant cells. For human
melanomas, two-dimensional protein analyses demonstrated down-
regulation of a high proportion of melanocyte proteins in
melanoma cell lines (Eberle et al, 1995a), and comparative
hybridization techniques subsequently identi®ed several down-
regulated genes including the pigmentation genes tyrosinase, TRP-1,
and TRP-2 (Eberle et al, 1995b, c) as well as the ET receptors
(Eberle et al, 1999).
Expression analyses and receptor binding assays identi®ed ET(B)-
R as predominant in melanocytic cells, whereas ET(A)-R was
expressed much more weakly. Compared to primary cultures of
normal melanocytes and of congenital nevus cells, ET(B)-R
mRNA and ET-1 binding was consistently downregulated in 16
of 17 melanoma cell lines analyzed, with the only exception the
highly differentiated and pigmented cell line SK-Mel-19.
Furthermore, comparison with pigment gene expression revealed
a close correlation with ET(B)-R expression whereas ET(A)-R
expression was contradictory (Eberle et al, 1999). In contrast to the
consistent cell culture data, immunohistochemistry and reverse
transcriptase polymerase chain reaction (RT-PCR) performed on
tumor samples very recently suggested an enhanced ET(B)-R
expression in melanoma metastases compared to primary tumor and
nevus samples (Demunter et al, 2001).
For different cell types it has been shown that ETs are also
involved in the regulation of apoptosis. Unlike the situation in
endothelial cells and smooth muscle cells, where a pro-survival
activity of ET-1 has been reported (Shichiri et al, 1997; Wu-Wong
et al, 1997), induction of apoptosis by ET-1 was described for the
human melanoma cell line A-375, after cell synchronization
(Okazawa et al, 1998).
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The present study was performed to clarify the role of ET for
melanoma cells and to investigate whether downregulation of ET
receptors found in melanoma cell lines may be understood as an
apoptosis escape of melanoma cells. It turned out, however, that
ET-1 results in a decrease rather than an increase of basic apoptotic
rates in most melanoma cell lines as in normal melanocytes. Cell
transfection experiments were further applied to con®rm this
®nding.
MATERIALS AND METHODS
Cultivation of normal melanocytes and melanoma cells Cultures
of normal human melanocytes were isolated from human foreskins after
trypsin digestion (Eisinger and Marco, 1982) and were grown in MCDB
153 (Biochrom, Berlin, Germany) supplemented with 2 mM Ca2+, 5 mg
per ml insulin (Sigma, St. Louis, MO), 10 mg per ml human transferrin
(Sigma), 0.4% bovine pituitary extract (Life Technologies, Karlsruhe,
Germany), 2 ng per ml bovine basic ®broblast growth factor (Boehringer
Mannheim, Germany), 1 nM cholera toxin (Calbiochem, La Jolla, CA),
and 50 mM hydrocortisone (Serva, Heidelberg, Germany). The use of
separated and anonymized foreskin tissue for cultivation of primary cell
cultures was approved by the local Ethical Committee of the University
Medical Center Benjamin Franklin.
Seven human melanoma cell lines were examined in this study: A-375
(Giard et al, 1973), Bro (Lockshin et al, 1985), M-5 (Liao et al, 1975),
Mel-2a (Bruggen et al, 1981), MeWo (Bean et al, 1975), SK-Mel-13,
and SK-Mel-19 (Carey et al, 1976). Melanoma cell lines were maintained
in Dulbecco's modi®ed Eagle's medium (DMEM) (4.5 g per l glucose;
Life Technologies) supplemented with 10% fetal bovine serum (FBS) and
antibiotics (Biochrom). For routine cultivation, cells were passaged at
70% con¯uence with 2 3 106 cells per 75 cm2 ¯ask. ET receptors were
in general downregulated in melanoma cell lines, as shown in a previous
paper (Eberle et al, 1999). As illustrated in Table I, only SK-Mel-19
showed an expression level of ET(B)-R comparable to normal melano-
cytes; Mel-2a, SK-Mel-13, and A-375 were characterized by moderate
expression of ET(B)-R, MeWo showed weak expression of ET(B)-R,
and M-5 showed weak expression of ET(A)-R. ET receptor expression
was nearly lost in the melanoma cell line Bro, which was characterized
by an approximately 1000-fold decrease of ET binding (Eberle et al,
1999; Table I).
Construction of expression plasmids and cell transfection The
full-length cDNA of ET(B)-R kindly provided by M. Paul, Department
of Clinical Pharmacology and Toxicology, UKBF, Berlin, was subcloned
as a BamHI fragment downstream of the CMV promoter in the
expression vector pBK-CMV (Stratagene, La Jolla, CA). For better
eucaryotic expression, the lactose promoter between CMV promoter and
cloning site was further deleted by fusion of the two restriction sites
NheI, which separates the two promoters, and SpeI within the cloning
site. Plasmid DNA used for transfection was extracted by plasmid
puri®cation kits of Qiagen (Hilden, Germany).
For melanoma cell transfection, lipofectin (Life Technologies) and
DNA were incubated separately for 30 min at room temperature in
serum-free DMEM (Life Technologies) and were then mixed and
incubated for another 10 min at room temperature. Cells at a con¯uence
of 40%±60%, in 75 cm2 ¯asks, were washed once and incubated at 37°C
with this solution containing 2 ml per ml lipofectin and 1 mg per ml
plasmid DNA. After 2 d, cells were washed and were then further
incubated with 400 mg per ml geneticin (Life Technologies) for selection.
Individual cell clones resistant to the antibiotic were selected by limited
dilution in microtiter plates.
Receptor binding assays A detailed protocol for determination of
relative numbers of ET-1 binding sites has been described previously
(Eberle et al, 1999). In brief, melanoma cells were seeded in 24-well
plates (2 3 105 cells per well). On the following day, when con¯uence
was about 50%±70%, growth medium was exchanged with serum-free
DMEM. After 24 h, cells were washed twice with ice-cold binding
buffer (50 mM HEPES, 5 mM MgCl2, 0.3% bovine serum albumin, pH
7.4) and incubated at 4°C in 200 ml of this buffer containing 0.125 mCi
of 125I ET-1 (2000 Ci per mmol; Amersham, Buckinghamshire, U.K.).
After 4 h of moderate shaking, supernatants were discarded and cells
were washed twice with cold binding buffer and lyzed for 45 min in 1
M NaOH at 37°C. Non-speci®c binding was determined in duplicate
wells preincubated for 30 min with a 100-fold excess of ET-1 (Sigma).
Radioactivity in the cellular fractions was measured with a gamma
counter (Packard, Meriden, CT). Values for unspeci®c binding were
subtracted from the total bound counts, and values were further
normalized by cell number.
Analysis of cell proliferation Cell proliferation was determined by
the thymidine incorporation assay (O'Keefe et al, 1988). Cells were
seeded in 96-well plates with 104 cells per well in appropriate growth
medium. After 24 h, cells were washed once and were incubated with
growth medium containing the intended concentration of FBS (0%, 3%,
or 10%). After another 24 h, medium was exchanged again and serum
concentration was maintained. ET-1 was added in a concentration of
10 nM or 100 nM, whereas the controls received the same volume of
50 mM acetic acid, the solution in which ET-1 was dissolved. After
20 h, cells were incubated for another 4 h with 2.5 mCi per ml 3H-
thymidine (68.5 Ci per mmol). Cells were harvested with a cell
harvester, and tritium incorporation was measured in a scintillation
counter.
Cell synchronization Synchronization of melanoma cells and normal
melanocytes was performed according to a protocol described by
Okazawa et al (1998). Growth medium for cell synchronization was
always prewarmed to 37°C and growth plates were handled outside the
cell incubator only for short periods of time in order to avoid cell cycle
interruption. Melanoma cells were seeded in 24-well plates (10,000±
30,000 cells per well). The seeding density was dependent on the
proliferation and cell shape of the respective cell line; a seeding density
was chosen such that cells were still subcon¯uent at the end of the
experiment. Normal melanocytes were seeded in six-well plates (2 3 105
cells per well). The utmost care was taken over seeding really equal cell
numbers. On the following day, synchronization was started by addition
of thymidine to a ®nal concentration of 2.5 mM. The thymidine block
was released after 16 h by washing the cells and further incubation with
growth medium containing 25 mM deoxycytidine. The second
thymidine block was started after another 9 h by washing the cells and
again treatment with 2.5 mM thymidine. The second block was released
also after 16 h by washing the cells and incubation in growth medium
containing 1% FBS (melanoma cells) and 25 mM deoxycytidine. Treated
cells received ET-1 whereas control cells received the same volume of
ET solution buffer.
Quanti®cation of apoptosis Apoptosis rates were measured of
synchronized cells (described above) as well as of nonsynchronized cells
24 h after stimulation with ET-1 by using the cell death detection
enzyme-linked immunosorbent assay (ELISA) (Roche Diagnostics,
Mannheim, Germany), which detects mononucleosomes and
oligonucleosomes formed in apoptotic cells; the protocol has been
described earlier (Wieder et al, 1998). Nonsynchronized cells were
seeded in 24-well and six-well plates, respectively, as described above for
synchronized cells. ELISA values of melanoma cells were normalized by
Table I. Expression of ET receptors in melanoma cell lines useda
Receptor NHMb SK-Mee19 SK-Mee13 Mel-2a A-375 MeWo M-5 Bro
ET(B)-R 100 108 19 22 13 5 PCRd PCR
ET(A)-Rc 0.3 ± ± ± ± PCR 4 0.1
aExpression values of the ET receptors were determined by northern blotting and were already reported in a previous study (Eberle et al, 1999).
bExpression of ET(B)-R in normal melanocytes (NHM) was set to 100%, and expression values of ET(B)-R in melanoma cell lines were calculated in percentage relative
to this value.
cExpression data for ET(A)-R were put into relation to ET(B)-R due to ET binding experiments, which yielded for M-5 80% of the ET-1 binding capacity determined
for MeWo.
dPCR is indicated when expression was not detectable by northern blotting; however, RT-PCR was positive.
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con¯uence of the cultures, and ELISA values of normal melanocytes
were normalized by cell numbers that had been determined in parallel
dishes. Relative apoptotic rates were calculated as the ratio of the
normalized values from treated and control cells.
Statistical analysis For statistical analysis, individual values (single
wells) of a given experiment were normalized by the mean value of
untreated cells in this experiment. Thus, values of independent
experiments could be combined in groups. To demonstrate statistical
signi®cance of enhanced cell proliferation or reduced apoptosis due to
ET-1 treatment, Student's t test was applied (unpaired and
heteroskedastic).
RESULTS
The mitogenic potential of ET-1 is much less pronounced in
melanoma cells than in normal melanocytes To investigate
the effects of ET-1 on cell proliferation, thymidine incorporation
was determined in normal melanocytes as well as in melanoma cell
lines after incubation with 10 nM and 100 nM ET-1, respectively.
As shown in Table II, a strong proliferation increase after
treatment with 10 nM ET-1 was observed for two independent
cultures of normal human melanocytes (6.3-fold 6 0.3 and 3.9-fold
6 0.8, respectively); application of 100 nM ET-1 did not further
increase proliferation. We investigated the proliferation effect in
SK-Mel-19 characterized by undiminished ET(B)-R expression
and in SK-Mel-13 characterized by moderate expression of ET(B)-
R. Both melanoma cell lines showed nearly no response when
cultured in standard growth medium containing 10% FBS. As
normal melanocytes were routinely grown serum-free, we further
investigated the in¯uence of FBS on the growth effects caused by
ET. The growth effects were slightly increased to 1.2-fold 6 0.1
(SK-Mel-19) and to 1.09-fold 6 0.05 (SK-Mel-13) when cells
were incubated with 3% FBS for 24 h before starting ET treatment,
but further decrease of FBS concentration to 0% did not enhance
the growth effect. Also, preincubation of normal melanocytes with
growth medium containing 10% FBS did not abolish the growth
response of normal melanocytes.
The effects of FBS alone on proliferation of melanoma cells were
investigated for SK-Mel-13. Cells that had been propagated with
10% FBS received a medium exchange with 0%, 3%, or 10% FBS,
and tritium incorporation was determined after 48 h, as had been
performed in the proliferation experiments. Reduction of FBS
concentration from 10% to 3% resulted in a reduction of thymidine
incorporation to 72% (p < 0.002), and reduction from 10% to 0%
resulted in reduced thymidine incorporation of 57% (p < 0.0001).
Other cell lines and normal melanocytes showed a comparable
tendency. Two cell lines characterized by weak expression of
ET(B)-R (MeWo) or extremely weak expression of ET(A)-R
(Bro) were also examined with 3% FBS, and showed no signi®cant
growth response. Unlike normal melanocytes, incubation with
100 nM ET-1 had no growth effect on SK-Mel-13, MeWo, and
Bro but resulted in growth inhibition for SK-Mel-19 (Table II).
Basic apoptotic rates are decreased by ET-1 both in normal
melanocytes and in melanoma cells The in¯uence of ET-1
on basic apoptotic rates was investigated in normal human
melanocytes and in seven melanoma cell lines characterized by
different expression levels of ET receptors (Table I). A ®rst series
of experiments performed with SK-Mel-19 revealed no signi®cant
difference between treatment with 10 nM and 100 nM ET-1 (data
not shown); for the following experiments, 100 nM ET was
applied. As proapoptotic effects by ET had been reported earlier for
the melanoma cell line A-375 only after cell synchronization
(Okazawa et al, 1998), we investigated both nonsynchronized
melanoma cells and normal melanocytes as well as cells after
synchronization.
To rule out the in¯uence of possibly increased cell numbers on
the apoptosis values, we determined cell numbers of SK-Mel-19
and of normal melanocytes in parallel with the apoptosis assays. It
turned out that cell numbers of normal melanocytes were
signi®cantly increased after treatment with ET-1 for 24 h, whereas
there was no change in cell numbers of SK-Mel-19 melanoma cells
(Table III). Consequently, we normalized all apoptosis values of
normal melanocytes by cell numbers. For SK-Mel-19, normal-
ization to actual cell numbers did not lead to any change in the
apoptosis values obtained. As other melanoma cell lines responded
even less to ET-1 with respect to proliferation (Table II),
normalization to cell numbers was not necessary for melanoma
cells.
In nonsynchronized cells, apoptosis was signi®cantly reduced in
SK-Mel-19 and normal human melanocytes both characterized by
a high expression of ET(B)-R (Fig 1A). After cell synchronization,
cell lines with moderate (SK-Mel-13 and Mel-2a) and weak
(MeWo) expression of ET(B)-R also showed an antiapoptotic
effect after ET-1 treatment. This was also true for M-5
characterized by weak ET(A)-R expression but lack of ET(B)-R
expression. No signi®cant response was seen for the cell line A-375
reported earlier, and for the cell line Bro, which almost completely
lacks ET receptor expression (Fig 1B).
To investigate whether the ET-1 responsibility lost in Bro cells
can be restored by ET(B)-R expression, Bro cells were stably
transfected with an ET(B)-R expression plasmid. Screening of
transfected cell clones by northern analysis revealed ®ve cell clones
(274a±e) characterized by relatively high expression of an ET(B)-
R-speci®c mRNA of 2450 nucleotides (Fig 2). The mRNA
length of 2450 nucleotides speci®cally expressed in the transfected
clones was in the range expected from the plasmid construct used.
Also, the cDNA probe for ET(B)-R used does not cross-react with
ET(A)-R as shown previously (Eberle et al, 1999). Therefore
speci®c expression of an ET(B)-R-speci®c mRNA was ensured.
This mRNA also resulted in expression of ET(B)-R active in
binding ET-1 as proven by binding assays. In the transfected cell
clones, ET-1 binding was enhanced between 10-fold and 50-fold
compared to the parent cell line Bro (Fig 3). As Bro cells show
only very weak ET-1 binding capacity, which is due to weak
expression of ET(A)-R as shown previously (Eberle et al, 1999), the
enhanced binding capacity of transfected cell clones is consequently
due to the overexpressed ET(B)-speci®c mRNA.
The melanoma cell line Bro does not reveal typical melanocyte
differentiation parameters and is completely negative for expression
Table II. Effects of ET-1 on cell proliferationa
10 nM ET-1 100nM ET-1
Cellsb %FBSc Mean SD p-valued Mean SD p-valued
NHM-A 0 6.27 0.28 <10-11 6.71 0.55 <10-8
NHM-B 0 3.87 0.82 <10-13 4.01 0.95 <10-12
NHM-B 10 2.13 0.27 < 0.003 1.71 0.10 < 0.03
SKM19 0 1.11 0.06 0.85 0.05 < 0.008
SKM19 3 1.20 0.10 < 0.005 0.86 0.04 < 0.05
SKM19 10 1.00 0.02 0.88 0.06
SKM13 0 1.07 0.02 1.03 0.22
SKM13 3 1.09 0.05 < 0.02 1.03 0.01
SKM13 10 1.07 0.05 0.96 0.06
Bro 3 1.04 0.02 1.02 0.05
MeWo 3 1.02 0.02 1.01 0.03
aProliferation rates were determined by thymidine incorporation; values repre-
sent the ratio of treated versus untreated cells (mean values of a minimum of three
experiments and standard deviation).
bTwo independent cultures of normal human melanocytes (NHM-A and
NHM-B) and four melanoma cell lines (SK-Mel-19, SK-Mel-13, MeWo, Bro)
were investigated.
cStandard growth medium of melanoma cells contained 10% FBS whereas stan-
dard melanocyte growth medium was serum-free. To investigate whether the miss-
ing response of melanoma cells to ET was due to the concentration of FBS in the
growth medium, melanoma cells were also grown with 3% FBS and serum-free,
and NHM-B were also grown with 10% FBS.
dp-values were calculated according to Student's t test, and are given when in-
creased thymidine incorporation after ET-1 treatment was statistically signi®cant
(NHM, SK-Mel-19, SK-Mel-13).
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of pigment gene mRNA as was shown in previous studies (Eberle
et al, 1995b). As ET(B)-R suppression in melanoma cells was found
in parallel with decreased pigment gene expression, we investigated
whether the transfected Bro cell clones, now positive for ET(B)-R
expression, also had consequent changes concerning their differen-
tiation. Morphology was unchanged, however, and northern
blotting revealed no expression of tyrosinase, TRP-1, and TRP-
2 as was typical for the parent cell line Bro (data not shown).
Reduced apoptotic rates in stably transfected Bro cells after
ET-1 treatment We further investigated the reactivity of two
transfected cell clones characterized by the highest expression of
ET(B)-R (274a and 274e). Proliferation was slightly enhanced in
274a after treatment with 10 nM ET-1 (1.16-fold 6 0.06) and
showed a tendency to decrease after treatment with 100 nM ET-1,
comparable to the growth response seen for SK-Mel-19. The
proliferation effects seen for 274e were not signi®cant but showed a
similar tendency (Table IV).
In nonsynchronized 274a and 274e cells, ET treatment did not
result in an antiapoptotic effect; however, after cell synchroniza-
tion, there was a signi®cant reduction of apoptosis after ET-1
treatment comparable to the effects seen for other ET(B)-R-
positive cell lines (Fig 4). Thus, it was shown that ET(B)-R can
mediate both proliferation stimulation and the antiapoptotic effects
caused by ET in melanoma cells.
DISCUSSION
Unlike other growth factors with predominantly mitogenic effects,
ET has been shown to enhance both proliferation and differenti-
ation of normal human melanocytes (Yada et al, 1991). A complex
signal transduction network including cross-talk between cAMP
and protein kinase C pathways has been suggested, and several steps
have already been con®rmed (Imokawa et al, 1996, 2000).
Enhanced thymidine incorporation after ET-1 treatment has
been reported for normal melanocytes (Yada et al, 1991; Imokawa
et al, 1992; 2000), whereas growth effects reported for melanoma
cell lines were weaker (Yohn et al, 1994; Kikuchi et al, 1996). A
direct comparison between normal melanocytes and melanoma cell
lines, however, has not yet been drawn, and the relation to ET
receptor expression has not been investigated.
For two melanocyte cultures, we determined an ET-1-depend-
ent proliferation increase of 4-fold and 6-fold, respectively, which
was in the same range as reported earlier. The ET-1 growth
response determined for four melanoma cell lines, however, was at
maximum 1.2-fold in the case of SK-Mel-19 characterized by
undiminished ET(B)-R expression, and it was not signi®cant for
other cell lines. The concentration of serum in the growth medium
was not critical for the different responses of normal melanocytes
and melanoma cells, as modi®cation of the growth conditions
proved. Thus, downregulation of ET receptors in melanoma cell
lines can only be partly responsible for the missing growth response
Table IV. Proliferation dependence on ET after ET(B)-R
transfectiona
Cellsb % FBSc
10 nM ET-1 100nM ET-1
Mean SD Mean SD
Bro 3 1.04 0.02 1.02 0.05
274a 3 1.19d 0.09 0.98 0.15
274e 3 1.05 0.07 0.96 0.18
aProliferation rates were determined by thymidine incorporation; values repre-
sent the ratio of treated versus untreated cells (mean values of a minimum of three
experiments and standard deviation).
bThe parent cell line Bro and two cell clones resulting from stable transfection
of Bro cells with ET(B)-R (274a and 274e) were investigated.
cConcentration of FBS was reduced to 3%, 24 h before treatment with ET-1.
dIncreased thymidine incorporation after treatment with 10 nM ET-1 was statis-
tically signi®cant for 274a.
Figure 1.ET-1 decreases basic apoptotic rates in melanocytic
cells. Apoptosis dependence on ET-1 was investigated in seven
melanoma cell lines (SK-Mel-19, A-375, SK-Mel-13, Mel-2a, MeWo,
M-5, and Bro) as well as in normal human melanocytes (NHM).
Cultures were treated with 100 nM ET-1 and were compared to parallel
untreated cultures. Bars represent the ratio of apoptotic rates after ET-1
treatment versus apoptosis in untreated cells (in percentage; deviation
from 100%). Experiments were performed with nonsynchronized cells
(A) and with cells after synchronization (B).Values of normal human
melanocytes were normalized to actual cell numbers as these were also
dependent on ET-1 treatment (see Table III). Experiments had been
repeated for several times, at least three experiments; bars represent mean
values of all experiments performed. Asterisks indicate statistical
signi®cance; p-values were determined by Student's t test.
Nonsynchronized cells: p < 0.0001 (SK-Mel-19); p < 0.00001 (NHM).
Synchronized cells: p < 0.001 (SK-Mel-19); p < 0.04 (SK-Mel-13); p
< 0.002 (Mel-2a); p < 0.0001 (MeWo); p < 0.02 (M-5); p < 0.006
(NHM). Expression of ET(B)-R after stable transfection in Bro cells.
Table III. Decreased cell numbers for normal melanocytes
after ET-1 treatment
Cellsa Synchr.b Cell numberc SDd p-valuese
NHM ± 1.35 0.28 < 0.02
NHM + 1.22 0.19 < 0.003
SKM-19 1.00 0.04
SKM-19 + 0.98 0.07
aCell numbers after ET-1 treatment were determined for six independent mela-
nocyte cultures (NHM) as well as for the melanoma cell line SK-MEL-19 charac-
terized by undiminished expression of ET(B)-R.
bCells were investigated both without (±) as well as after cell synchronization
(+).
cCell numbers were counted after treatment with 100 nM ET-1 and were com-
pared to untreated cells. Mean values are given of the ratio of treated versus un-
treated cells (+/±).
dStandard deviation (SD)
eIncreased cell numbers in NHM cultures after ET-1 treatment were statistically
signi®cant; p-values were calculated according to Student's t test.
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to ET, and melanoma cell proliferation has become independent of
ET even when ET receptors are expressed.
Concerning the effect of ET on melanocyte differentiation,
increased tyrosinase activities have been found in cultured normal
melanocytes after ET-1 stimulation (Yada et al, 1991), and
increased tyrosinase activity and mRNA levels for tyrosinase and
TRP-1 were reported to accompany elevated ET-1 levels in UVB-
exposed human epidermis (Imokawa et al, 1995). Furthermore,
downregulation of pigmentation genes in melanoma cell lines
was in parallel to ET(B)-R downregulation (Eberle et al, 1999).
Decreased ET(B)-R expression, however, seems not to be the
direct cause for downregulation of pigmentation genes in
melanoma cell lines, as stable transfection of unpigmented Bro
cells with ET(B)-R did not result in an onset of pigment gene
expression.
For targeting cancer cells, induction of apoptosis appears a
promising strategy and a number of apoptosis-regulating factors
have already been identi®ed. Also ETs are involved in the
regulation of apoptosis as shown for several cell types. For vascular
cells (endothelial cells and smooth muscle cells), an antiapoptotic
potential of ET has been reported (Shichiri et al, 1997; Wu-Wong
et al, 1997), and relations between the ET signal and apoptosis
signal transduction pathways were shown (Diep et al, 2000; Egidy et
al, 2000; Shichiri et al, 2000). But under certain growth conditions,
ET was also able to enhance nitric oxide induced apoptosis in
smooth muscle cells (Nakahashi et al, 1998), and in ET-1 transgenic
mice an increased number of apoptotic kidney cells were found
(Hocher et al, 1998).
For cancer cells, an antiapoptotic activity of ET-1 was reported
for colon carcinoma and glioblastoma, where Fas-ligand-induced
apoptosis could be enhanced by ET receptor antagonists (Eberl et al,
Figure 2. Overexpression of ET(B)-R mRNA in stably
transfected Bro melanoma cells. A northern blot probed with an
ET(B)-R-speci®c cDNA fragment is shown of total RNA isolated from
Bro melanoma cells, which is completely negative for ET(B)-R
expression, and of ®ve cell clones selected after stable transfection of Bro
cells with the full-length ET(B)-R cDNA (274a±e). MeWo represents a
melanoma cell line with relatively weak expression of the two ET(B)-R-
speci®c mRNA species (4300 and 1600 nucleotides), and was used as a
positive control for the ET(B)-R-speci®c probe. Stable transfection of
ET(B)-R cDNA resulted in a prominent, ET(B)-R-speci®c, band of
2450 nucleotides, which re¯ects the length of the subcloned cDNA plus
transcribed vector sequences.
Figure 3. Overexpression of ET(B)-R in Bro cells resulted in
increased binding capacities for ET-1. Relative binding capacities for
ET-1 were determined by receptor binding assay. They are shown for
®ve cell clones derived after stable transfection of a full-length ET(B)-R
cDNA into Bro cells (274a±e). For comparison, the binding capacity of
the parent cell line Bro was determined in parallel and was set to 1.
Stable transfection of ET(B)-R cDNA resulted in a 10-fold to 50-fold
increase of the ET-1 binding capacity. The basic binding capacity of Bro
cells is due to weak expression of ET(A)-R.
Figure 4. ET-1 reduced apoptosis in Bro cells stably transfected
with ET(B)-R. Apoptosis dependence on ET-1 was investigated in two
cell clones derived after stable transfection of Bro cells with the full-
length ET(B)-R cDNA (274a and 274e) and in the parent cell line Bro,
which is essentially negative for ET(B)-R expression. The apoptosis
dependence of SK-Mel-19 characterized by undiminished ET(B)-R
expression is shown as a positive control. Cultures were treated with
100 nM ET-1 and were compared to parallel untreated cultures. Bars
represent the ratio (in percentage; deviation from 100%) of basic
apoptotic rates in cells stimulated with ET-1 versus control cells. The
experiment was performed with nonsynchronized cells (A) and with cells
after synchronization (B). Asterisks indicate statistical signi®cance.
Experiments had been repeated several times, at least three experiments,
and p-values were determined by Student's t test. Synchronized cells: p
< 0.02 (274a); p < 0.02 (274e); p-values for SK-Mel-19, see legend to
Fig 1.
VOL. 119, NO. 3 SEPTEMBER 2002 ET-1 DECREASES APOPTOSIS 553
2000; Egidy et al, 2000). For human melanoma cells, there were
two contradictory reports: whereas the human melanoma cell line
A-375 was shown to respond with increased apoptosis to ET-1
treatment, after cell synchronization (Okazawa et al, 1998), ET
receptor antagonists resulted in growth inhibition and induced cell
death in other melanoma cell lines in vitro and in nude mice (Lahav
et al, 1999).
In this study, we found that ET-1 clearly decreased basic
apoptotic rates in normal melanocytes as well as in SK-Mel-19
characterized by undiminished expression of ET(B)-R. In other
cell lines with moderate expression of ET receptors, the
antiapoptotic potential was seen after cell synchronization. No
signi®cant response was seen for A-375 cells described earlier
(Okazawa et al, 1998) and for Bro cells, which almost
completely lack any ET receptor expression. In this respect, it
is interesting to note that the antiapoptotic response could be
restored in Bro cells after overexpression of ET(B)-R, indicating
that the effectors for the ET-1 signal cascade were active in
these cells and that the antiapoptotic effect of ET-1 is mediated
in a receptor-speci®c way.
The implications of the antiapoptotic effect of ET-1 for
melanoma cells has to be seen in the context of the regulation of
its receptors. In our previous studies, we had shown consistent
downregulation of ET(B)-R in cultured melanoma cell lines
compared to primary cultures of normal melanocytes and nevus
cells (Eberle et al, 1999). Recent investigations on tumor samples,
however, revealed enhanced ET(B)-R expression in melanoma
metastases compared to primary tumor and nevus samples
(Demunter et al, 2001). Such differences between in vivo and
in vitro gene expression cannot be explained by unrepresentative
gene expression in tumor cell lines, as 16 of 17 melanoma cell lines
investigated showed similar downregulation of ET(B)-R; instead,
different availabilities of cytokines in vivo may be the cause. As
shown for vascular cells, ET receptors are subject to several control
mechanisms including transcription factors AP-1 and C/EBP
(Cattaruzza et al, 2001). Several cytokines are secreted by epidermal
keratinocytes and by vascular cells including ET-1 itself (Halaban,
1996), which may be candidates for triggering ET(B)-R upregula-
tion in melanoma cells in vivo.
In conclusion, our data clearly demonstrate that ET-1 is
antiapoptotic for melanoma cells as for normal melanocytes; the
growth response, however, is diminished in melanoma cells even
when ET receptors are suf®ciently expressed. Upregulation of ET
receptors in melanoma cells shown in vivo in combination with the
reduction of basic apoptotic rates by ET found here may critically
contribute to melanoma progression. When thinking of a thera-
peutic approach for melanoma, receptor antagonists (Lahav et al,
1999) or antisense strategies against ET receptors in combination
with gene targeting using tyrosinase promoters (Park et al, 1999)
might be helpful; however, such strategies have to compete with
other possible proapoptotic strategies.
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